# Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

> **NCT01677572** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 197 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01677572
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10-05
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 197 (ACTUAL)
- **Why stopped:** Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01677572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01677572, "Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01677572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*